Loading stock data…
BAX
$20.86+0.37 (+1.81%)
Market ClosedLast close Jun 12
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Baxter International Inc. in the Healthcare sector is trading at $20.86. Wall Street consensus targets $21.54 (12 analysts), implying a +3.3% move over the next 12 months. The stock is currently 34% below its 52-week high of $31.76, remaining 5.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.70B↓ | $2.97B↑ | $2.83B↑ | $2.81B↑ | $2.63B |
| Gross Profit | $891.00M↑ | $577.00M↓ | $950.00M↓ | $991.00M↑ | $861.00M |
| Operating Income | $66.00M↑ | -$244.00M↓ | $172.00M↓ | $191.00M↑ | $58.00M |
| Net Income | -$15.00M↑ | -$1.13B↓ | -$46.00M↓ | $91.00M↓ | $126.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.91%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.17%
Volume
Today's trading volume
6.28M
Recent News
3 Unpopular Stocks We’re Skeptical Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Is Baxter International Inc. (BAX) A Good Stock To Buy Now?
Is BAX a good stock to buy? We came across a bullish thesis on Baxter International Inc. on Heavy Moat Investments’s Substack. In this article, we will summarize the bulls’ thesis on BAX. Baxter International Inc.’s share was trading at $20.03 as of June 9th. BAX’s forward P/E was 10.20 according to Yahoo Finance. Baxter International (BAX) […]
DaVita Stock Gains From Integrated Kidney Care and CKCC Progress
DVA expands its IKC platform, tops CKCC savings in first-quarter 2026 and rolls out AI ScheduleHub to boost scheduling and staffing.
Baxter International (BAX) Faces Tough Road Ahead, Says Citi in Downgrade
With a TTM operating cash flow of $1.25 billion, Baxter International Inc. (NYSE:BAX) is included among the 12 Cash-Rich Stocks to Buy Right Now. On May 28, Citi analyst Joanne Wuensch downgraded Baxter International Inc. (NYSE:BAX) to Sell from Neutral. She lowered the price target on the stock to $17 from $19. In a research note, the […]
FMS and Home Dialysis: How 5008X Could Reset Demand
FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.